GRI Bio, Inc. — Form 8-K Summary
Business context and reporting period
GRI Bio filed a Form 8-K dated June 7, 2024, reporting the results of a Special Meeting of Stockholders held virtually on the same date. The filing concerns corporate governance actions and does not report quarterly or annual operating results.
Key financial and corporate metrics
- Common shares issued and outstanding and eligible to vote as of May 1, 2024: 3,774,488.
- Shares present or represented by proxy: 1,727,613, or approximately 45.8% of eligible shares, constituting a quorum.
- No revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics were reported in this filing.
Material changes and voting results
| Proposal | For | Against | Abstained | Result |
|---|---|---|---|---|
| Amendment to authorize a reverse stock split at a ratio between 1-for-2 and 1-for-15, with the final ratio and implementation subject to Board discretion | 1,417,003 | 310,490 | 120 | Approved |
| Potential postponement or adjournment to solicit additional proxies | 1,427,587 | 270,321 | 29,705 | Approved |
The reverse stock split amendment does not reduce the authorized number of common shares. The Board may determine the precise split ratio within the approved range or abandon the reverse stock split. The filing does not state that the split had been effected as of June 7, 2024.
Guidance, outlook, risks, and unusual items
- The principal unusual corporate action is the stockholder authorization for a potential reverse stock split, which could affect the number of outstanding shares and per-share trading metrics if implemented.
- Implementation timing, the selected ratio, and whether the Board will proceed were not specified in the filing.
- No management financial guidance, operating outlook, contingencies, or additional risk disclosures were provided.
Investor verification points
- Verify whether the Board subsequently implemented the reverse stock split and, if so, the effective date and ratio.
- Assess the resulting change in shares outstanding, authorized shares, and per-share data.
- Review subsequent SEC filings for financing activity, Nasdaq listing implications, liquidity, and updated corporate actions.
- Confirm the detailed voting procedures and proposal descriptions in the definitive proxy statement filed May 9, 2024.